These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38615521)

  • 1. Mechanisms of therapeutic change after psychedelic treatment in OCD.
    Maloney G; Ching T; Kichuk SA; Pittenger C; Kelmendi B
    Psychiatry Res; 2024 Jun; 336():115907. PubMed ID: 38615521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psilocybin for the Treatment of Obsessive-Compulsive Disorders.
    Ehrmann K; Allen JJB; Moreno FA
    Curr Top Behav Neurosci; 2022; 56():247-259. PubMed ID: 34784024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imagery Rescripting for Anxiety Disorders and Obsessive-Compulsive Disorder: Recent Advances and Future Directions.
    Strachan LP; Hyett MP; McEvoy PM
    Curr Psychiatry Rep; 2020 Feb; 22(4):17. PubMed ID: 32076845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imagery rescripting as an adjunct clinical intervention for obsessive compulsive disorder.
    Maloney G; Koh G; Roberts S; Pittenger C
    J Anxiety Disord; 2019 Aug; 66():102110. PubMed ID: 31357037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder.
    Moreno FA; Wiegand CB; Taitano EK; Delgado PL
    J Clin Psychiatry; 2006 Nov; 67(11):1735-40. PubMed ID: 17196053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psilocybin and Obsessive Compulsive Disorder.
    Wilcox JA
    J Psychoactive Drugs; 2014; 46(5):393-5. PubMed ID: 25364991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Classic psychedelic drugs and their potential therapeutic effect].
    Bayat M
    Ugeskr Laeger; 2017 Sep; 179(37):. PubMed ID: 28918777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imagery Rescripting for Obsessive Compulsive Disorder: A single case experimental design in 12 cases.
    Veale D; Page N; Woodward E; Salkovskis P
    J Behav Ther Exp Psychiatry; 2015 Dec; 49(Pt B):230-236. PubMed ID: 25805628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematized Review of Psychotherapeutic Components of Psilocybin-Assisted Psychotherapy.
    Horton DM; Morrison B; Schmidt J
    Am J Psychother; 2021 Dec; 74(4):140-149. PubMed ID: 34293927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psilocybin for Trauma-Related Disorders.
    Khan AJ; Bradley E; O'Donovan A; Woolley J
    Curr Top Behav Neurosci; 2022; 56():319-332. PubMed ID: 35711024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of imagery rescripting on core beliefs and eating disorder symptoms in a subclinical population.
    Kadriu F; Claes L; Witteman C; Woelk M; Krans J
    J Behav Ther Exp Psychiatry; 2023 Mar; 78():101804. PubMed ID: 36435546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin.
    Carhart-Harris RL; Leech R; Williams TM; Erritzoe D; Abbasi N; Bargiotas T; Hobden P; Sharp DJ; Evans J; Feilding A; Wise RG; Nutt DJ
    Br J Psychiatry; 2012 Mar; 200(3):238-44. PubMed ID: 22282432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hallucinogens and obsessive-compulsive disorder.
    Perrine DM
    Am J Psychiatry; 1999 Jul; 156(7):1123. PubMed ID: 10401480
    [No Abstract]   [Full Text] [Related]  

  • 14. An Investigation of Cognitive and Affective Changes During Group Imagery Rescripting for Social Anxiety Disorder.
    McCarthy A; Bank SR; Campbell BNC; Summers M; Burgess M; McEvoy P
    Behav Ther; 2022 Sep; 53(5):1050-1061. PubMed ID: 35987535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history.
    Pearson C; Siegel J; Gold JA
    J Neurol Sci; 2022 Mar; 434():120096. PubMed ID: 34942586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should cognitive restructuring precede imagery rescripting? An experimental pilot study.
    Voncken MJ; Janssen I; Keijsers GPJ; Dibbets P
    J Behav Ther Exp Psychiatry; 2023 Mar; 78():101800. PubMed ID: 36435542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of imagery rescripting on consolidated memories of an aversive film.
    Siegesleitner M; Strohm M; Wittekind CE; Ehring T; Kunze AE
    J Behav Ther Exp Psychiatry; 2019 Mar; 62():22-29. PubMed ID: 30176538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psilocybin-assisted therapy for depression: How do we advance the field?
    Meikle SE; Liknaitzky P; Rossell SL; Ross M; Strauss N; Thomas N; Murray G; Williams M; Castle DJ
    Aust N Z J Psychiatry; 2020 Mar; 54(3):225-231. PubMed ID: 31752499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DARK Classics in Chemical Neuroscience: Psilocybin.
    Geiger HA; Wurst MG; Daniels RN
    ACS Chem Neurosci; 2018 Oct; 9(10):2438-2447. PubMed ID: 29956917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences?
    Majić T; Schmidt TT; Gallinat J
    J Psychopharmacol; 2015 Mar; 29(3):241-53. PubMed ID: 25670401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.